275 related articles for article (PubMed ID: 8254015)
21. Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys.
Stroup GB; Kumar S; Jerome CP
Calcif Tissue Int; 2009 Oct; 85(4):344-55. PubMed ID: 19763376
[TBL] [Abstract][Full Text] [Related]
22. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
23. Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge.
Spadaro JA; Damron TA; Horton JA; Margulies BS; Murray GM; Clemente DA; Strauss JA
J Orthop Res; 2006 May; 24(5):936-44. PubMed ID: 16609966
[TBL] [Abstract][Full Text] [Related]
24. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
Adachi JD; Saag KG; Delmas PD; Liberman UA; Emkey RD; Seeman E; Lane NE; Kaufman JM; Poubelle PE; Hawkins F; Correa-Rotter R; Menkes CJ; Rodriguez-Portales JA; Schnitzer TJ; Block JA; Wing J; McIlwain HH; Westhovens R; Brown J; Melo-Gomes JA; Gruber BL; Yanover MJ; Leite MO; Siminoski KG; Nevitt MC; Sharp JT; Malice MP; Dumortier T; Czachur M; Carofano W; Daifotis A
Arthritis Rheum; 2001 Jan; 44(1):202-11. PubMed ID: 11212161
[TBL] [Abstract][Full Text] [Related]
25. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
26. The bone architecture is enhanced with combined PTH and alendronate treatment compared to monotherapy while maintaining the state of surface mineralization in the OVX rat.
Campbell GM; Bernhardt R; Scharnweber D; Boyd SK
Bone; 2011 Aug; 49(2):225-32. PubMed ID: 21515436
[TBL] [Abstract][Full Text] [Related]
27. Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: comparison with pamidronate and etidronate in growing rats.
Azuma Y; Oue Y; Kanatani H; Ohta T; Kiyoki M; Komoriya K
J Pharmacol Exp Ther; 1998 Jul; 286(1):128-35. PubMed ID: 9655851
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamic responses to combined treatment regimens with the calcium sensing receptor antagonist JTT-305/MK-5442 and alendronate in osteopenic ovariectomized rats.
Fisher JE; Scott K; Wei N; Zhao JZ; Cusick T; Tijerina M; Karanam B; Duong L; Glantschnig H
Bone; 2012 Jun; 50(6):1332-42. PubMed ID: 22445539
[TBL] [Abstract][Full Text] [Related]
29. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice.
Pierroz DD; Bouxsein ML; Rizzoli R; Ferrari SL
Bone; 2006 Aug; 39(2):260-7. PubMed ID: 16531131
[TBL] [Abstract][Full Text] [Related]
30. [Effects of Dioscorea septemloba on bone metabolism in ovariectomized rats].
Xing GS; Lou JS; Wang ZB; Yu SL; Wang Y; Sheng L
Zhongguo Zhong Yao Za Zhi; 2007 Sep; 32(18):1909-13. PubMed ID: 18051905
[TBL] [Abstract][Full Text] [Related]
31. Effects of alendronate and strontium ranelate on cancellous and cortical bone mass in glucocorticoid-treated adult rats.
Sun P; Cai DH; Li QN; Chen H; Deng WM; He L; Yang L
Calcif Tissue Int; 2010 Jun; 86(6):495-501. PubMed ID: 20390406
[TBL] [Abstract][Full Text] [Related]
32. Preclinical pharmacology of alendronate.
Rodan GA; Seedor JG; Balena R
Osteoporos Int; 1993; 3 Suppl 3():S7-12. PubMed ID: 8298203
[TBL] [Abstract][Full Text] [Related]
33. Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia.
Duong LT; Crawford R; Scott K; Winkelmann CT; Wu G; Szczerba P; Gentile MA
Bone; 2016 Dec; 93():86-96. PubMed ID: 27639811
[TBL] [Abstract][Full Text] [Related]
34. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats.
Li X; Ominsky MS; Warmington KS; Niu QT; Asuncion FJ; Barrero M; Dwyer D; Grisanti M; Stolina M; Kostenuik PJ; Simonet WS; Paszty C; Ke HZ
Endocrinology; 2011 Sep; 152(9):3312-22. PubMed ID: 21733832
[TBL] [Abstract][Full Text] [Related]
35. Bone functional changes in intact, ovariectomized, and ovariectomized, hormone-supplemented adult cynomolgus monkeys (Macaca fascicularis) evaluated by serum markers and dynamic histomorphometry.
Jerome CP; Carlson CS; Register TC; Bain FT; Jayo MJ; Weaver DS; Adams MR
J Bone Miner Res; 1994 Apr; 9(4):527-40. PubMed ID: 8030441
[TBL] [Abstract][Full Text] [Related]
36. Comparison of calcitonin, alendronate and fluorophosphate effects on ovariectomized rat bone.
Giavaresi G; Fini M; Gnudi S; Aldini NN; Rocca M; Carpi A; Giardino R
Biomed Pharmacother; 2001 Sep; 55(7):397-403. PubMed ID: 11669503
[TBL] [Abstract][Full Text] [Related]
37. Effect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate.
Yano T; Yamada M; Inoue D
Calcif Tissue Int; 2017 Jul; 101(1):102-110. PubMed ID: 28337514
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength.
Sakai S; Endo K; Takeda S; Mihara M; Shiraishi A
Bone; 2012 May; 50(5):1054-63. PubMed ID: 22366400
[TBL] [Abstract][Full Text] [Related]
39. Effects of eight-month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys.
Ochi Y; Yamada H; Mori H; Nakanishi Y; Nishikawa S; Kayasuga R; Kawada N; Kunishige A; Hashimoto Y; Tanaka M; Sugitani M; Kawabata K
Bone; 2014 Aug; 65():1-8. PubMed ID: 24784023
[TBL] [Abstract][Full Text] [Related]
40. The effect of androstenedione/estrone supplementation on cortical and cancellous bone in the young intact female monkey: a model for the effects of polycystic ovarian disease on the skeleton?
Lundon KM; Jayo MJ; Register TC; Dumitriu M; Grynpas MD
Osteoporos Int; 2000; 11(9):778-89. PubMed ID: 11210841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
